Formulations of pimavanserin
DCFirst Claim
Patent Images
1. A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a capsule shell with a capsule shell size 3 or 4, that encapsulates a blended pimavanserin composition comprising:
- 40 mg granulated pimavanserin tartrate having a particle size distribution (D90) of 180 to 340 μ
m, wherein the bulk density of the granulated pimavanserin is 0.4 to 0.6 g/ml as determined by USP<
616>
, method 1;
59 mg microcrystalline cellulose having a particle size distribution (D90) of 180 to 340 μ
m; and
1 mg magnesium stearate;
wherein the particle size distribution is measured using laser light scattering with a Malvern Mastersizer 2000 LLS PS system, a Scirocco 2000 dry dispersion unit and a sample size of 2 to 10 g.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
-
Citations
5 Claims
-
1. A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a capsule shell with a capsule shell size 3 or 4, that encapsulates a blended pimavanserin composition comprising:
-
40 mg granulated pimavanserin tartrate having a particle size distribution (D90) of 180 to 340 μ
m, wherein the bulk density of the granulated pimavanserin is 0.4 to 0.6 g/ml as determined by USP<
616>
, method 1;59 mg microcrystalline cellulose having a particle size distribution (D90) of 180 to 340 μ
m; and1 mg magnesium stearate;
wherein the particle size distribution is measured using laser light scattering with a Malvern Mastersizer 2000 LLS PS system, a Scirocco 2000 dry dispersion unit and a sample size of 2 to 10 g. - View Dependent Claims (2)
-
-
3. A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to patient, wherein the capsule has a size 4 capsule shell that contains a blended pimavanserin composition comprising:
-
40% w/w pimavanserin tartrate, wherein the bulk density of the pimavanserin tartrate is 0.4 to 0.6 g/ml as determined by USP <
616>
, method 1;59% w/w microcrystalline cellulose; wherein the D90 particle size distribution of the blended pimavanserin composition is 100 to 300 μ
m as measured using laser scattering particle size analysis, and the capsule contains the 34 mg pimavanserin.- View Dependent Claims (4, 5)
-
Specification